News Release

Taiho Pharma Singapore


 

Taiho Pharmaceutical Co., Ltd.

2017

02/06/2017 Taiho Pharmaceutical to Construct Facility for Production of Highly Potent Pharmaceutical Ingredients
18/05/2017 Taiho Pharmaceutical Receives Approval for the Additional Indications of Complicated Skin and Soft Tissue Infections for ZOSYN®, an Injectable Antibiotic Combined with β-lactamase Inhibitor
03/04/2017 Taiho Pharmaceutical Completely Redesigns Official Website
07/03/2017 Taiho Pharmaceutical Announces Expansion into Canada

2016

18/11/2016 Taiho and Meiji Announce the Launch of Bilanoa® Tablets 20 mg, an Oral Anti-allergy Drug in Japan (PDF:64KB)
28/09/2016 Taiho Pharmaceutical Receives Approval to Manufacture and Market Bilanoa® Tablets, an Oral Anti-allergy Drug in Japan
30/08/2016 UK’s NICE Recommends LONSURF® (trifluridine/tipiracil) As Treatment of Previously Treated Metastatic Colorectal Cancer - Taiho’s Partner Servier to Market LONSURF in UK - (PDF:240KB)
25/08/2016 New Drink-Type Gingyo-san (lonicerae and forsythia powder) Containing 10 Varieties of Herbal Medicine to Be Launched on August 25, 2016 Works for Early Symptoms of Common Cold Such As Sore Throat and Cough (PDF:149KB)
29/07/2016 Application for Additional Indications of Complicated Skin and Soft Tissue Infections (Including Diabetic Foot Infections) for ZOSYN®, an Injectable Antibiotic Combined with β-lactamase Inhibitor
10/05/2016 Taiho Pharmaceutical Forms Taiho Ventures to Foster Oncology Biotech Start-ups
28/04/2016 Patients with Advanced Metastatic Colorectal Cancer in Europe Now Have New Treatment Option as LONSURF® (trifluridine/tipiracil) Receives EU Approval
11/04/2016 Tiovita series to go on sale outside Japan Tiovita 3000 to Be Released in Hong Kong “Supporting the hard workers of Hong Kong”
11/04/2016 MSD and Taiho Enter into Co-Promotion Agreement in Japan for Pembrolizumab, MSD’s Immune Checkpoint Inhibitor (Anti-PD-1 Therapy) (PDF:148KB)
01/04/2016 Taiho’s TAS-102 Meets Primary Endpoint of Improving Overall Survival in
Phase III TERRA Study in Asian Patients with Refractory Metastatic Colorectal Cancer
15/03/2016 Taiho Pharmaceutical Announces Personnel Changes (PDF:76KB)
29/02/2016 CHMP Issues Positive Opinion for LONSURF® (trifluridine/tipiracil) for
Refractory Metastatic Colorectal Cancer
26/02/2016 Toray, Nanotheta, Taiho to Accelerate Business of Antiadhesive Material Based on Nano-scale Polymer Thin Film Technology (PDF:146KB)

2015

17/12/2015 Taiho and Meiji Enter Into a Co-marketing Agreement in Japan for TAC-202(bilastine), a Treatment for Allergic Disorders
26/11/2015 NHI Reimbursement Price Listing and Launch of the Novel Antitumor Agent
“Yondelis® IV Infusion”
13/11/2015 Taiho Pharmaceutical Submits Application for Approval to Manufacture and Market
TAC-202 (bilastine), an Oral Anti-allergy Drug in Japan
28/09/2015 Novel Antitumor Agent “Yondelis® IV Infusion” Approved in Japan for Treatment of Soft Tissue Sarcoma
24/09/2015 Taiho Pharmaceutical Announces FDA Approval of LONSURF® (trifluridine and tipiracil) for Refractory Metastatic Colorectal Cancer (mCRC)
01/09/2015 The First Pre-Meal Drink in the Solmack Series "Solmack 5 Herbal Digestive Support" Nationwide Launch in Japan on Monday, September 7
26/06/2015 ZOSYN® Receives Approval for the Additional Indication of Febrile Neutropenia
15/06/2015 Taiho Pharmaceutical Co., Ltd. and Servier Enter Into a License Agreement for Development and Commercialization of an Oral Anticancer Drug TAS-102 in Europe
01/06/2015 Support for modern people in the prime of life! Designated quasi-drug Tiovita Gold α (Alpha) mini-drink to be launched throughout Japan on June 22
14/05/2015 Results from Global Phase III Trial of TAS-102 (brand name in Japan: "Lonsurf® ") Published in The New England Journal of Medicine
20/03/2015 Lonsurf® Combination Tablet for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer Receives Approval in Japan for Partial Change in Indications
02/03/2015 Taiho Submits TAS-102 (brand name in Japan: "Lonsurf®") Marketing Authorization Application to the European Medicines Agency for the Treatment of Refractory Metastatic Colorectal Cancer
23/02/2015 Taiho Pharmaceutical Announces TAS-102 (brand name in Japan: "Lonsurf®") New Drug Application for Refractory Metastatic Colorectal Cancer Accepted for Review by FDA
05/01/2015 Taiho Pharmaceutical Receives Approval to Manufacture and Market ZOSYN® 4.5 for I.V. Infusion Bag, an Injectable Antibiotic Combined with β-Lactamase Inhibitor

2014

24/12/2014 Taiho Pharmaceutical Completes Submission of TAS-102 New Drug Application to the US Food and Drug Administration for the Treatment of Refractory Metastatic Colorectal Cancer
18/12/2014 Antitumor Agent "Abraxane® I.V. Infusion 100 mg" Approved for Additional Indication of Unresectable Pancreatic Cancer
21/10/2014 Taiho Pharmaceutical Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer
– Taiho Initiates Rolling NDA Submission for TAS-102 –
31/07/2014 Taiho Pharmaceutical Announces Termination of Phase III Clinical Trial of the Angiogenesis Inhibitor TSU-68 (orantinib) in Patients with Hepatocellular Carcinoma
25/07/2014 Phase III Clinical Study of S-1 in Patients with Advanced Hepatocellular Carcinoma Did Not Meet Its Primary Endpoint
23/07/2014 Taiho Pharmaceutical Invests US$ 30 Million in Remiges BioPharma Fund, LP to Foster Early Biotech Start-ups
02/07/2014 Application for the Additional Indication of Febrile Neutropenia for ZOSYN®, an Injectable Antibiotic Combined with β-Lactamase Inhibitor
30/06/2014 Taiho Pharmaceutical Announces Results from TAS-102 Global Phase III RECOURSE Trial in Refractory Metastatic Colorectal Cancer
11/06/2014 Taiho Pharmaceutical Announces Personnel Changes (PDF:132KB)
04/06/2014 Data from Phase II Trial of ET-743 (trabectedin), a Novel Antitumor Agent, in Patients with Malignant Soft Tissue Sarcoma Presented at ASCO®
03/06/2014 Results of Phase III Clinical Study (SELECT BC) of TS-1 Treatment for Metastatic Breast Cancer Announced at ASCO®
23/05/2014 Anticancer Drug Lonsurf® Combination Tablet Receives NHI Reimbursement Price Listing and is Scheduled for Launch
12/05/2014 Taiho Oncology's TAS-102 Meets Primary Endpoint of Improving Overall Survival in Global Phase III RECOURSE Trial in Refractory Metastatic Colorectal Cancer
22/04/2014 ET-743 (trabectedin), a Novel Antitumor Agent Meets Primary Endpoint of Progression Free Survival Prolongation in a Phase 2 Trial in Malignant Soft Tissue Sarcoma Patients
24/03/2014 Taiho's Lonsurf® (trifluridine and tipiracil hydrochloride) Tablets Approved in Japanfor Treatment in Advanced Metastatic Colorectal Cancer
06/01/2014 Transfer of Astellas' Fermentation Research-Related Assets to Taiho Pharmaceutical (PDF:153KB)

2013

11/11/2013 Phase III Clinical Trial Results of TS-1 on Metastatic Colorectal Cancer Published in Digital Version of The Lancet Oncology
25/09/2013 Cancer Pain Reliever E-fen Buccal Tablets Launched (PDF:121KB)
11/09/2013 Results of a Clinical Trial (JACCRO GC-05) of Second-line TS-1 Therapy on Patients with Unresectable or Recurrent Gastric Cancer That Is Refractory to Initial Therapy with TS-1
21/06/2013 Anticancer Agent TS-1 Combination OD Tablets T20, T25 to Be Launched in Japan
06/06/2013 Results of Phase III Trials of TS-1 on Patients with Colorectal Cancer and Head and Neck Cancers Announced at ASCO®
24/05/2013 New Plant Constructed in Tokushima Prefecture
To Serve as Production Center for Anti-cancer Drugs
03/04/2013 Results of the Phase III Clinical Study (GEST) of TS-1 in Patients with Advanced Pancreatic Cancer Published in the Online Version of the Journal of Clinical Oncology
27/02/2013 Taiho Pharmaceutical Submits Application for Approval to Manufacture and Market Novel Antitumor Agent TAS-102
21/02/2013 Antitumor Agent "ABRAXANE® I.V. Infusion 100 mg" Approved for Additional Indications of Gastric Cancer and Non-small Cell Lung Cancer
13/02/2013 Condition for Approval (All-Patient Enrollment)of ABRAXANE® I.V. Infusion 100mg Antineoplastic Removed
28/01/2013 Resected Pancreatic Cancer Announced at the Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology

2012

30/11/2012 Announcement; Launch of 5-HT3 Receptor Antagonist Aloxi® I.V. infusion bag 0.75mg
28/09/2012 ZOSYN®, an Injectable Antibiotic Combination Product Receives an Approval for Peritonitis,
Intra-abdominal Abscess, Cholecystitis, and Cholangitis
18/09/2012 Clinical Trial (JASPAC 01) of TS-1 for Resected Pancreatic Cancer
28/08/2012 Results of a Phase II Clinical Trial for the Novel Antitumor Agent TAS-102 Posted on the Electronic Edition of The Lancet Oncology
24/07/2012 Taiho and Faes Farma (Spain) Enter into a License Agreement on Anti-Allergy Agent
11/07/2012 Business Partnership regarding Breakthrough Cancer Pain Reliever
22/06/2012 Launch of Histamine H2 Receptor Antagonist PROTECADIN® OD Tablets (Orally Disintegrating Tablet)
06/06/2012 Phase III Clinical Trial (CATS TRIAL) for Non-small-cell Lung Cancer Non-inferiority of TS-1 + Cisplatin Treatment Verified Presented to the American Society of Clinical Oncology (ASCO)
31/05/2012 Taiho Pharmaceutical Announces the Start of a Global Phase III Clinical Trial in Metastatic Colorectal Cancer with the Novel Antitumor Agent TAS-102
16/04/2012 Distributor change for Lentinan I.V. Infusion 1mg “Ajinomoto”, an anti-tumor agent
11/04/2012 Taiho Pharmaceutical’s Anticancer Agent TS-1 Approved for Market in Hong Kong
11/04/2012 Anti-Cancer Drug Teysuno® has been launched in the United Kingdom.
30/03/2012 Termination of co-development of a β3-adrenoceptor agonist
21/03/2012 Taiho Pharmaceutical’s Anticancer Agent TS-1 Approved for Market in Thailand
21/03/2012 Anti-Cancer Drug Teysuno® has been launched in Sweden, Denmark, Norway and Finland
09/03/2012 Licensing Agreement Cancelled for NST-141 Agent for Pruritus in Atopic Dermatitis
01/03/2012 ABRAXANE® I.V. Infusion 100mg Application Submitted for Approval of Additional Indications in Japan

2011

12/12/2011 Taiho Pharmaceutical Announces Personnel Changes
12/09/2011 Taiho Pharmaceutical to Launch a New Anti-tumor Agent, ZOLINZA® capsules 100mg, on September 14